A pilot double-blind, randomized, placebo-controlled trial of curcumin/bioperine for lung cancer chemoprevention in patients with chronic obstructive pulmonary disease

• 作者: Amir Sharafkhaneh Bharat Aggarwal Burton Dickey Carol J. Farhangfar Cherise Acosta Diane Liu Hanan Abdel-Monem Ignacio I. Wistuba J. Jack Lee Jonathan M. Kurie Nancy Caraway Nga Bich Nguyen Nicola Hanania Robert Newman Ruth Katz Seyed J. Moghaddam Waun K. Hong
• 来源期刊: 肺癌(英文)
• 学科: 医学
• 关键词: Lung Cancer Inflammation NUTRACEUTICAL Agents COPD Cytological ABNORMALITIES
• 年，卷（期）: fayw_2013,（3）
• 页码范围: 62-69
• 页数: 8页
• 分类号: R73

摘要

Chronic obstructive pulmonary disease is an inflammatory condition with increased risk of lung cancer. We hypothesized that curcumin/ bioperine (CB), which has anti-inflammatory effects, may reduce cytological abnormalities in the sputum of patients with COPD. We conducted a 3-month, three-to-one randomized, doubleblind, pilot trial of escalating doses of CB in patients with moderate or worse COPD who were capable of producing sputum. The primary efficacy endpoint was changed in sputum cytology. We also explored changes in fluorescence in situ hybridization (FISH). We obtained sputum samples for cytology and chromosome abnormalities at baseline and each monthly follow-up visit. We enrolled 57 participants, with 35 completing the study. The participants’ mean age (standard deviation [SD]) was 66.6 (8.2) years, and they were mainly male (91.2%), with an average of 63.8 pack-years of smoking history. Also, 42.1% of participants were active smokers and the mean (SD) FEV1 was 37% (13%). At baseline, 13 subjects had moderate or worse dysplasia (22.8%). Subjects with moderate to severe sputum dysplasia had more chromosome abnormalities in epithelial cells and neutrophils, as measured by deletion and aneuploidy in 10q22.3. The changes in sputum cytology and chromosome abnormalities did not differ between the active and placebo arms. CB was well tolerated at the bid doses of 1, 1.5, and 2 gm of curcumin and 5 mg of bioperine, with minor side effects related to the gastrointestinal tract. In this short pilot trial, CB compared to placebo did not alter cytological and chromosomal abnormalities seen in sputum of patients with COPD.